P08620
PR
Gene name |
FGF4 (HST, HSTF1, KS3) |
Protein name |
Fibroblast growth factor 4 |
Names |
FGF-4, Heparin secretory-transforming protein 1, HST, HST-1, HSTF-1, Heparin-binding growth factor 4, HBGF-4, Transforming protein KS3 |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:2249 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
2 structures for P08620
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 1IJT | X-ray | 180 A | A | 79-206 | PDB |
| AF-P08620-F1 | Predicted | AlphaFoldDB |
167 variants for P08620
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| TCGA novel | 2 | S>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs961929512 CA223506176 |
3 | G>E | No |
ClinGen TOPMed |
|
|
rs1367222161 CA381663222 |
4 | P>T | No |
ClinGen TOPMed gnomAD |
|
|
CA381663205 rs1390579117 |
6 | T>M | No |
ClinGen gnomAD |
|
|
CA381663203 rs1300071377 |
7 | A>P | No |
ClinGen gnomAD |
|
|
CA381663195 rs1334783518 |
8 | A>E | No |
ClinGen gnomAD |
|
|
rs1405367069 CA381663198 |
8 | A>S | No |
ClinGen gnomAD |
|
|
CA381663196 rs1405367069 |
8 | A>T | No |
ClinGen gnomAD |
|
|
rs1345315922 CA381663165 |
13 | P>R | No |
ClinGen TOPMed |
|
|
rs1158890592 CA381663158 |
14 | A>V | No |
ClinGen gnomAD |
|
|
rs1405375767 CA381663156 |
15 | V>I | No |
ClinGen gnomAD |
|
|
rs759707481 CA6156989 |
18 | A>D | No |
ClinGen ExAC gnomAD |
|
|
CA381663138 rs759707481 |
18 | A>V | No |
ClinGen ExAC gnomAD |
|
|
CA381663123 rs1437006409 |
21 | A>T | No |
ClinGen TOPMed |
|
|
rs1462632542 CA381663113 |
22 | P>L | No |
ClinGen gnomAD |
|
|
rs1201213049 CA381663116 |
22 | P>S | No |
ClinGen TOPMed gnomAD |
|
|
rs1468828259 CA381663107 |
23 | W>* | No |
ClinGen TOPMed |
|
|
CA381663101 rs906608234 |
24 | A>E | No |
ClinGen TOPMed |
|
|
rs776891803 CA6156988 |
24 | A>T | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA223506162 rs906608234 |
24 | A>V | No |
ClinGen TOPMed |
|
|
CA6156986 rs747109892 |
26 | R>Q | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA381663089 rs1382292721 |
27 | G>R | No |
ClinGen gnomAD |
|
|
CA381663087 rs1382292721 |
27 | G>W | No |
ClinGen gnomAD |
|
|
CA6156985 rs773226560 |
28 | G>S | No |
ClinGen ExAC gnomAD |
|
|
CA6156984 rs184198236 |
29 | A>V | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
rs1347254164 CA381663070 |
30 | A>D | No |
ClinGen gnomAD |
|
|
rs1452104529 CA381663071 |
30 | A>S | No |
ClinGen gnomAD |
|
|
rs1439982023 CA381663065 |
31 | A>G | No |
ClinGen gnomAD |
|
|
rs779951764 CA381663067 |
31 | A>P | No |
ClinGen ExAC gnomAD |
|
|
rs779951764 CA6156982 |
31 | A>T | No |
ClinGen ExAC gnomAD |
|
|
CA6156981 rs769732384 |
32 | P>L | No |
ClinGen ExAC gnomAD |
|
|
rs1256805085 CA381663028 |
37 | G>D | No |
ClinGen gnomAD |
|
|
rs1424999450 CA381663031 |
37 | G>S | No |
ClinGen gnomAD |
|
|
rs1484773540 CA381663017 |
39 | L>Q | No |
ClinGen gnomAD |
|
| TCGA novel | 40 | E>K | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1217041826 CA381663005 |
41 | A>T | No |
ClinGen gnomAD |
|
|
CA381663000 rs1359046966 |
42 | E>K | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
CA381662991 rs1313142602 |
43 | L>V | No |
ClinGen gnomAD |
|
|
rs895323790 CA381662972 |
46 | R>C | No |
ClinGen TOPMed |
|
|
rs895323790 CA223506126 |
46 | R>G | No |
ClinGen TOPMed |
|
|
rs1054010007 CA223506123 |
46 | R>L | No |
ClinGen Ensembl |
|
|
rs1368149178 CA381662967 |
47 | W>G | No |
ClinGen TOPMed |
|
|
rs924238902 CA223506116 |
54 | S>L | No |
ClinGen Ensembl |
|
| TCGA novel | 55 | L>F | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA6156978 rs756925670 |
56 | A>V | No |
ClinGen ExAC gnomAD |
|
|
CA381662895 rs1424386120 |
58 | L>P | No |
ClinGen gnomAD |
|
|
CA381662891 rs1335396702 |
59 | P>S | No |
ClinGen TOPMed |
|
|
CA381662885 rs1399829479 |
60 | V>L | No |
ClinGen gnomAD |
|
|
rs902415700 CA223506113 |
64 | P>S | No |
ClinGen TOPMed gnomAD |
|
|
rs1043621727 CA223506112 |
67 | A>T | No |
ClinGen TOPMed gnomAD |
|
|
CA381662832 rs1474520052 |
68 | A>D | No |
ClinGen TOPMed |
|
|
rs1411878660 CA381662827 |
69 | V>F | No |
ClinGen gnomAD |
|
|
CA381662802 rs1265209064 |
72 | G>D | No |
ClinGen gnomAD |
|
|
rs1194157859 CA381662796 |
73 | A>V | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs758863297 CA6156975 |
74 | G>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA381662786 rs1383383982 |
75 | D>V | No |
ClinGen TOPMed |
|
|
CA223506100 rs922987433 |
75 | D>Y | No |
ClinGen gnomAD |
|
|
rs1250882382 CA381662782 |
76 | Y>H | No |
ClinGen gnomAD |
|
|
CA381662768 rs1473382527 |
78 | L>Q | No |
ClinGen gnomAD |
|
|
rs754225864 CA6156971 |
83 | L>R | No |
ClinGen ExAC gnomAD |
|
|
CA223506081 rs760825703 |
85 | R>W | No |
ClinGen ExAC gnomAD |
|
|
rs772306812 CA381662693 CA6156967 |
90 | V>L | No |
ClinGen ExAC gnomAD |
|
|
CA381662687 rs1266598072 |
91 | G>D | No |
ClinGen gnomAD |
|
|
rs934056828 CA223506070 |
91 | G>S | No |
ClinGen TOPMed gnomAD |
|
|
CA381662674 rs1194178508 |
93 | G>D | No |
ClinGen gnomAD |
|
|
rs1250040489 CA381662676 |
93 | G>R | No |
ClinGen gnomAD |
|
|
rs775542907 CA6156965 |
94 | F>S | No |
ClinGen ExAC |
|
|
rs1259280329 CA381662650 |
97 | Q>K | No |
ClinGen gnomAD |
|
|
CA223506058 rs745670123 |
98 | A>G | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs745670123 CA6156963 |
98 | A>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA381662627 rs1234384702 |
100 | P>L | No |
ClinGen gnomAD |
|
|
rs1331360213 CA381662622 |
101 | D>G | No |
ClinGen gnomAD |
|
|
rs1331436166 CA381662609 |
103 | R>H | No |
ClinGen gnomAD |
|
|
rs1331436166 CA381662607 |
103 | R>L | No |
ClinGen gnomAD |
|
|
CA381662610 rs1401762674 |
103 | R>S | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs1469284144 CA381662602 |
104 | I>N | No |
ClinGen gnomAD |
|
|
rs1174143141 CA381662599 |
105 | G>S | Variant assessed as Somatic; 0.0003118 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs1363460000 CA381662588 |
106 | G>V | No |
ClinGen gnomAD |
|
|
rs1590951390 CA381662584 |
107 | A>E | No |
ClinGen Ensembl |
|
|
rs1189876184 CA381662571 |
109 | A>S | No |
ClinGen TOPMed |
|
|
rs752246982 CA6156957 |
111 | T>N | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs757882735 CA6156958 |
111 | T>S | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs779390973 CA6156956 |
112 | R>G | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs755540122 CA6156955 |
112 | R>H | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA6156953 rs766661168 |
113 | D>Y | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA223506026 rs1001068009 |
114 | S>C | No |
ClinGen gnomAD |
|
|
rs751631078 CA6156931 |
114 | S>R | No |
ClinGen ExAC gnomAD |
|
|
CA381662522 rs1182504779 |
116 | L>M | No |
ClinGen gnomAD |
|
|
rs1055730205 CA223505725 |
118 | L>F | No |
ClinGen Ensembl |
|
|
rs1432374845 CA381662505 |
118 | L>R | No |
ClinGen TOPMed |
|
|
CA381662500 rs1240828791 |
119 | S>W | No |
ClinGen TOPMed gnomAD |
|
|
CA381662493 rs1179344852 |
120 | P>L | No |
ClinGen gnomAD |
|
|
CA381662489 rs1488795759 |
121 | V>A | No |
ClinGen gnomAD |
|
|
rs776410631 CA6156928 |
121 | V>L | No |
ClinGen ExAC gnomAD |
|
|
rs1263476584 CA381662484 |
122 | E>G | No |
ClinGen gnomAD |
|
|
CA6156927 rs766381502 |
123 | R>W | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs539419605 CA6156925 |
124 | G>S | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
rs1245810774 CA381662471 |
124 | G>V | No |
ClinGen gnomAD |
|
|
CA381662470 rs747806374 |
125 | V>L | No |
ClinGen ExAC gnomAD |
|
|
rs747806374 CA6156923 |
125 | V>M | No |
ClinGen ExAC gnomAD |
|
|
CA381662464 rs1401631287 |
126 | V>M | No |
ClinGen gnomAD |
|
|
rs768068982 CA6156921 |
127 | S>T | No |
ClinGen ExAC gnomAD |
|
|
CA6156920 rs374997743 |
128 | I>F | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs979866825 CA223505681 |
130 | G>S | No |
ClinGen Ensembl |
|
|
CA381662432 rs756709205 CA6156918 |
131 | V>L | No |
ClinGen ExAC gnomAD |
|
|
CA381662428 rs1165619004 |
132 | A>T | No |
ClinGen gnomAD |
|
|
CA381662420 rs1409407660 |
133 | S>G | No |
ClinGen TOPMed gnomAD |
|
|
CA223505677 rs966807008 |
133 | S>I | No |
ClinGen Ensembl |
|
|
rs1418024352 CA381662415 |
134 | R>G | No |
ClinGen gnomAD |
|
|
rs1590951083 CA381662413 |
134 | R>P | No |
ClinGen Ensembl |
|
|
CA381662408 rs1590951080 |
135 | F>V | No |
ClinGen Ensembl |
|
|
rs1449019505 CA381662394 |
137 | V>M | No |
ClinGen TOPMed |
|
|
rs1487330048 CA381662385 |
138 | A>G | No |
ClinGen gnomAD |
|
|
CA6156916 rs781699363 |
138 | A>T | No |
ClinGen ExAC gnomAD |
|
|
rs757487910 CA6156915 |
139 | M>L | No |
ClinGen ExAC gnomAD |
|
|
CA6156913 rs751853747 CA381662339 |
144 | K>N | No |
ClinGen ExAC gnomAD |
|
|
rs1283278927 CA381662333 |
145 | L>P | No |
ClinGen gnomAD |
|
|
CA381662326 rs61738964 |
146 | Y>* | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA6156912 rs764426431 |
146 | Y>C | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA381662322 rs1190463033 |
147 | G>A | No |
ClinGen TOPMed |
|
|
CA381662300 rs1467905383 |
149 | P>A | No |
ClinGen TOPMed gnomAD |
|
|
CA381662301 rs1467905383 |
149 | P>T | No |
ClinGen TOPMed gnomAD |
|
|
CA381662293 rs1360173314 |
150 | F>V | No |
ClinGen gnomAD |
|
|
CA223505489 rs1042028355 |
151 | F>L | No |
ClinGen Ensembl |
|
|
CA223505479 rs533842802 |
153 | D>H | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA6156893 rs533842802 |
153 | D>N | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA6156892 rs779058257 |
154 | E>G | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs756008893 CA6156891 |
155 | C>S | No |
ClinGen ExAC gnomAD |
|
|
CA6156890 rs750386794 |
156 | T>M | No |
ClinGen ExAC gnomAD |
|
|
CA381662236 rs1179983115 |
158 | K>M | No |
ClinGen gnomAD |
|
|
CA6156888 rs145463849 |
160 | I>M | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA223505440 rs386754668 |
160 | I>MF | No |
ClinGen Ensembl |
|
|
CA381662225 rs1242209825 |
160 | I>V | No |
ClinGen TOPMed |
|
|
CA6156887 rs140567674 |
161 | L>F | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
| TCGA novel | 162 | L>F | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 163 | P>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 163 | P>S | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA381662198 rs1413186512 |
164 | N>S | No |
ClinGen gnomAD |
|
|
rs1288378265 CA381662189 |
165 | N>I | No |
ClinGen gnomAD |
|
|
CA381662188 rs1240994590 |
165 | N>K | No |
ClinGen gnomAD |
|
|
rs986306143 CA223505433 |
166 | Y>H | No |
ClinGen Ensembl |
|
|
rs930844659 CA223505429 |
167 | N>S | No |
ClinGen Ensembl |
|
|
COSM1207073 rs201349393 CA6156884 |
168 | A>T | large_intestine [Cosmic] | No |
ClinGen cosmic curated ExAC TOPMed gnomAD |
|
CA381662147 rs1182350769 |
171 | S>Y | No |
ClinGen TOPMed |
|
|
CA381662119 rs1422163301 |
175 | P>H | No |
ClinGen TOPMed |
|
|
rs150074947 CA6156881 |
175 | P>S | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA6156877 rs772115968 |
176 | G>A | No |
ClinGen ExAC gnomAD |
|
|
CA6156878 rs550329316 |
176 | G>C | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA6156879 rs550329316 |
176 | G>S | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
rs1419255315 CA381662107 |
177 | M>I | No |
ClinGen TOPMed |
|
|
CA223505392 rs992524703 |
178 | F>L | No |
ClinGen Ensembl |
|
|
rs748429697 CA6156876 |
179 | I>T | No |
ClinGen ExAC gnomAD |
|
|
CA381662061 rs1192709955 |
184 | N>S | No |
ClinGen gnomAD |
|
|
rs781106458 CA6156872 |
189 | K>M | No |
ClinGen ExAC gnomAD |
|
|
rs781106458 CA381662024 |
189 | K>R | No |
ClinGen ExAC gnomAD |
|
|
CA223505383 COSM1704319 rs866953016 |
190 | G>E | Variant assessed as Somatic; impact. skin [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated Ensembl NCI-TCGA |
|
rs780362260 CA381662015 |
191 | N>D | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA381662010 rs1217707093 |
191 | N>K | No |
ClinGen gnomAD |
|
|
rs780362260 CA6156870 |
191 | N>Y | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA6156869 rs751257747 |
192 | R>Q | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA gnomAD |
|
rs763955342 COSM1676259 CA6156867 |
194 | S>L | Variant assessed as Somatic; 0.0 impact. haematopoietic_and_lymphoid_tissue [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD |
|
CA6156865 rs752416500 |
195 | P>A | No |
ClinGen ExAC gnomAD |
|
|
rs200870263 CA6156864 |
197 | M>V | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
| TCGA novel | 199 | V>A | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA6156862 rs776338094 |
206 | L>M | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA6156861 rs766932837 |
206 | L>P | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA381661912 rs1590950791 |
207 | L>C | No |
ClinGen Ensembl |
1 associated diseases with P08620
Without disease ID
No regional properties for P08620
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| No domain, repeats, and functional sites for P08620 | |||
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| extracellular region | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. |
| extracellular space | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. |
3 GO annotations of molecular function
| Name | Definition |
|---|---|
| fibroblast growth factor receptor binding | Binding to a fibroblast growth factor receptor (FGFR). |
| growth factor activity | The function that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation. |
| heparin binding | Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues. |
26 GO annotations of biological process
| Name | Definition |
|---|---|
| animal organ morphogenesis | Morphogenesis of an animal organ. An organ is defined as a tissue or set of tissues that work together to perform a specific function or functions. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions. |
| apoptotic process involved in morphogenesis | Any apoptotic process that contributes to the shaping of an anatomical structure. |
| cartilage condensation | The condensation of mesenchymal cells that have been committed to differentiate into chondrocytes. |
| cell differentiation | The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state. |
| cell-cell signaling | Any process that mediates the transfer of information from one cell to another. This process includes signal transduction in the receiving cell and, where applicable, release of a ligand and any processes that actively facilitate its transport and presentation to the receiving cell. Examples include signaling via soluble ligands, via cell adhesion molecules and via gap junctions. |
| cellular response to leukemia inhibitory factor | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a leukemia inhibitory factor stimulus. |
| chondroblast differentiation | The process in which a mesenchymal cell, acquires specialized structural and/or functional features of a chondroblast. Differentiation includes the processes involved in commitment of a cell to a chondroblast fate. A chondroblast is a precursor cell to chondrocytes. |
| cranial suture morphogenesis | The process in which any suture between cranial bones is generated and organized. |
| embryonic hindlimb morphogenesis | The process, occurring in the embryo, by which the anatomical structures of the hindlimbs are generated and organized. The hindlimbs are the posterior limbs of an animal. |
| epithelial cell apoptotic process | Any apoptotic process in an epithelial cell. |
| fibroblast growth factor receptor signaling pathway | The series of molecular signals generated as a consequence of a fibroblast growth factor receptor binding to one of its physiological ligands. |
| mesenchymal cell proliferation | The multiplication or reproduction of cells, resulting in the expansion of a mesenchymal cell population. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets. |
| negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| odontogenesis of dentin-containing tooth | The process whose specific outcome is the progression of a dentin-containing tooth over time, from its formation to the mature structure. A dentin-containing tooth is a hard, bony organ borne on the jaw or other bone of a vertebrate, and is composed mainly of dentin, a dense calcified substance, covered by a layer of enamel. |
| positive regulation of cell division | Any process that activates or increases the frequency, rate or extent of cell division. |
| positive regulation of cell population proliferation | Any process that activates or increases the rate or extent of cell proliferation. |
| positive regulation of ERK1 and ERK2 cascade | Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. |
| positive regulation of gene expression | Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA). |
| positive regulation of protein phosphorylation | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. |
| positive regulation of stem cell proliferation | Any process that activates or increases the frequency, rate or extent of stem cell proliferation. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| regulation of cell migration | Any process that modulates the frequency, rate or extent of cell migration. |
| regulation of endothelial cell chemotaxis to fibroblast growth factor | Any process that modulates the frequency, rate or extent of endothelial cell chemotaxis to fibroblast growth factor. |
| signal transduction | The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell. |
| somatic stem cell population maintenance | Any process by which an organism retains a population of somatic stem cells, undifferentiated cells in the embryo or adult which can undergo unlimited division and give rise to cell types of the body other than those of the germ-line. |
| stem cell proliferation | The multiplication or reproduction of stem cells, resulting in the expansion of a stem cell population. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells. |
28 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P48801 | FGF3 | Fibroblast growth factor 3 | Gallus gallus (Chicken) | SS |
| Q92914 | FGF11 | Fibroblast growth factor 11 | Homo sapiens (Human) | SS |
| Q9NSA1 | FGF21 | Fibroblast growth factor 21 | Homo sapiens (Human) | PR |
| Q9HCT0 | FGF22 | Fibroblast growth factor 22 | Homo sapiens (Human) | SS |
| O15520 | FGF10 | Fibroblast growth factor 10 | Homo sapiens (Human) | SS |
| P11487 | FGF3 | Fibroblast growth factor 3 | Homo sapiens (Human) | SS |
| P31371 | FGF9 | Fibroblast growth factor 9 | Homo sapiens (Human) | EV |
| P10767 | FGF6 | Fibroblast growth factor 6 | Homo sapiens (Human) | SS |
| O43320 | FGF16 | Fibroblast growth factor 16 | Homo sapiens (Human) | EV SS |
| Q9NP95 | FGF20 | Fibroblast growth factor 20 | Homo sapiens (Human) | SS |
| P21658 | Fgf6 | Fibroblast growth factor 6 | Mus musculus (Mouse) | SS |
| Q9ESS2 | Fgf22 | Fibroblast growth factor 22 | Mus musculus (Mouse) | SS |
| O35565 | Fgf10 | Fibroblast growth factor 10 | Mus musculus (Mouse) | SS |
| P54130 | Fgf9 | Fibroblast growth factor 9 | Mus musculus (Mouse) | SS |
| Q9JJN1 | Fgf21 | Fibroblast growth factor 21 | Mus musculus (Mouse) | PR |
| Q9ESL8 | Fgf16 | Fibroblast growth factor 16 | Mus musculus (Mouse) | SS |
| Q9ESL9 | Fgf20 | Fibroblast growth factor 20 | Mus musculus (Mouse) | SS |
| P61329 | Fgf12 | Fibroblast growth factor 12 | Mus musculus (Mouse) | PR |
| P05524 | Fgf3 | Fibroblast growth factor 3 | Mus musculus (Mouse) | SS |
| P11403 | Fgf4 | Fibroblast growth factor 4 | Mus musculus (Mouse) | PR |
| Q95L12 | FGF9 | Fibroblast growth factor 9 | Sus scrofa (Pig) | SS |
| Q9EST9 | Fgf20 | Fibroblast growth factor 20 | Rattus norvegicus (Rat) | SS |
| O54769 | Fgf16 | Fibroblast growth factor 16 | Rattus norvegicus (Rat) | SS |
| P36364 | Fgf9 | Fibroblast growth factor 9 | Rattus norvegicus (Rat) | SS |
| P70492 | Fgf10 | Fibroblast growth factor 10 | Rattus norvegicus (Rat) | SS |
| Q6PBT8 | fgf1 | Putative fibroblast growth factor 1 | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| Q2HXK8 | fgf16 | Fibroblast growth factor 16 | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| P48802 | fgf3 | Fibroblast growth factor 3 | Danio rerio (Zebrafish) (Brachydanio rerio) | SS |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MSGPGTAAVA | LLPAVLLALL | APWAGRGGAA | APTAPNGTLE | AELERRWESL | VALSLARLPV |
| 70 | 80 | 90 | 100 | 110 | 120 |
| AAQPKEAAVQ | SGAGDYLLGI | KRLRRLYCNV | GIGFHLQALP | DGRIGGAHAD | TRDSLLELSP |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VERGVVSIFG | VASRFFVAMS | SKGKLYGSPF | FTDECTFKEI | LLPNNYNAYE | SYKYPGMFIA |
| 190 | 200 | ||||
| LSKNGKTKKG | NRVSPTMKVT | HFLPRL |